Brokerages expect Calyxt Inc (NASDAQ:CLXT) to post ($0.25) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Calyxt’s earnings, with the highest EPS estimate coming in at ($0.23) and the lowest estimate coming in at ($0.27). Calyxt reported earnings per share of ($0.24) during the same quarter last year, which would suggest a negative year over year growth rate of 4.2%. The business is expected to announce its next quarterly earnings results on Tuesday, March 12th.
On average, analysts expect that Calyxt will report full-year earnings of ($0.93) per share for the current year, with EPS estimates ranging from ($1.02) to ($0.86). For the next fiscal year, analysts forecast that the firm will post earnings of ($1.05) per share, with EPS estimates ranging from ($1.23) to ($0.90). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of analysts that follow Calyxt.
Calyxt (NASDAQ:CLXT) last released its quarterly earnings data on Wednesday, November 14th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.29) by $0.06. Calyxt had a negative return on equity of 33.08% and a negative net margin of 6,256.67%. The business had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.50 million.
NASDAQ:CLXT traded down $0.62 during midday trading on Friday, reaching $10.37. 51,098 shares of the company traded hands, compared to its average volume of 63,703. Calyxt has a twelve month low of $10.21 and a twelve month high of $27.23. The firm has a market capitalization of $337.77 million, a P/E ratio of -9.26 and a beta of 3.34. The company has a debt-to-equity ratio of 0.17, a current ratio of 15.01 and a quick ratio of 15.01.
In other Calyxt news, insider Daniel F. Voytas sold 4,083 shares of the business’s stock in a transaction dated Thursday, November 8th. The stock was sold at an average price of $13.00, for a total value of $53,079.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Manoj Sahoo sold 2,521 shares of the business’s stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $14.84, for a total value of $37,411.64. The disclosure for this sale can be found here. Insiders sold 20,553 shares of company stock worth $303,275 in the last 90 days. Corporate insiders own 2.80% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of CLXT. Tower Research Capital LLC TRC boosted its stake in shares of Calyxt by 134.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,583 shares of the company’s stock worth $123,000 after acquiring an additional 3,781 shares in the last quarter. Blair William & Co. IL boosted its stake in shares of Calyxt by 8.8% during the 3rd quarter. Blair William & Co. IL now owns 52,681 shares of the company’s stock worth $804,000 after acquiring an additional 4,280 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Calyxt by 12.1% during the 2nd quarter. Northern Trust Corp now owns 63,779 shares of the company’s stock worth $1,191,000 after acquiring an additional 6,903 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Calyxt by 2.0% during the 3rd quarter. Vanguard Group Inc. now owns 377,640 shares of the company’s stock worth $5,766,000 after acquiring an additional 7,246 shares in the last quarter. Finally, PNC Financial Services Group Inc. bought a new stake in shares of Calyxt during the 2nd quarter worth about $186,000. Hedge funds and other institutional investors own 28.30% of the company’s stock.
Calyxt Company Profile
Calyxt, Inc, a consumer-centric food- and agriculture-focused company, develops healthier specialty food ingredients and food crops using gene-editing technology for plants in the United States. It engages in the development of high oleic soybeans, high fiber wheat, herbicide tolerant wheat, powdery mildew resistant wheat, improved oil composition canola, herbicide tolerant canola, improved quality alfalfa and herbicide tolerant alfalfa, late blight resistant potatoes, cold storable/reduced browning potatoes, improved protein composition soybeans, drought tolerant soybeans, herbicide tolerant soybeans, and improved yield soybeans.
Further Reading: How is Preferred Stock Different from Common Stock?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Calyxt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calyxt and related companies with MarketBeat.com's FREE daily email newsletter.